37．Niwa Y, Mizushima Y．Neutrophil-potentiating factors released from stimulated lymphocytes: special reference to the increase in neutrophil-potentiating factors from streptococcus-stimulated lymphocytes of the patients with Behcet'ｓ disease. Clin Exp Immunol 79,353-360,1990．

38．Wechsler B, Davatch F, Mizushima Y, et al (International Study Group for Behcet'ｓ Disease):Criteria for diagnosis of Behcet's disease. Lancet 335,1078- 1080,1990．

39．Hoshi K, Mizushima Y．A preliminary double-blind cross-over trial of lipo-PGI2, a prostacyclin derivative incorporated in lipid microspheres, in cerebral infarction. Prostaglandins 40,155-164,1990．

40．Yokochi T, Yanagawa A, Nakagawa T, Mizushima Y．Titer and specificity of autoantibody to β2-microglobulin in sera from patients with rheumatic diseases. Microbiol Immunol 34,926-936,1990．

41．Mizushima Y． Streptococcus and Behcet'ｓ disease. In: Behcet's Disease. JD O'Duffy & E Kokmen, eds, Marcel Dekker, New York, 421-426,1990．

42．Mizushima Y, Igarashi R．Lipid microspheres and lecithinized polymer drug for drug delivery systems. In: Polymeric Drugs and Drug Delivery Systems, RL Dunn& RM Ottenbrite,eds, American Chemical Society, Washington DC, 267-274,1991．

43．Mizushima Y, Hamano T, Haramoto S, Kiyokawa S, Yanagawa A, Nakura K, Shintome M, Watanabe M．Distribution of lipid microspheres incorporating prostaglandin E1 to vascular lesions. Prostaglandins Leukot Essent Fatty Acids 41,269-272,1991．

44．Mizushima Y, Igarashi R．Studies on polypeptide drug delivery systems: tissue distribution of immunoglobulin G conjugated with lecithin. J Controlled Release 17,99-104,1991．

45．Lehner T, Lavery R, Smith R, van der Zee R, Mizushima Y, Shinnick T．Association between the 65-kilodalton heat shock protein, streptococcus sanguis, and the corresponding antibodies in Behcet's syndrome. Infec Immun 59,1434-1441,1991．

46．Mochizuki M, Masuda K, Sakane T, Mizushima Y, et al: A multicenter open trial of FK506 in uveitis including Behcet's disease.Transplant Proc 23,3343- 3346,1991．

47．Mizushima Y, Igarashi R．Lipid microsphere preparations and lecithinized peptides for drug delivery systems. In: Medical Chemistry for the 21st Century. CG Wermuth, N Koga, H Konig, BW Metcalf, eds, Blackwell Scientific Publications, Amsterdam, 381-397,1992．

48．Igarashi R, Mizushima Y, Takenaga M, Matsumoto K, Morizawa Y, Yasuda A．A stable PGE1 prodrug for targeting therapy. J Controlled Release 20,37-46, 1992．

49．Igarashi R, Hoshino J, Takenaga M, Kawai S, Morizawa Y, Yasuda A, Otani M, Mizushima Y．Lecithinization of superoxide dismutase potentiates its protective effect agatinst forssman antiserum induced elevation in guinea pig airway resistance. J Pharmacol Exp Ther 262,1214-1219,1992．

50．Mizoguchi M, Kawaguchi K, Ohsuga Y, Ikari Y, Yanagawa A, Mizushima Y．Cyclosporin ointment for psoriasis and atopic dermatitis.Lancet 339,1120,1992．

51．Hirohata S, Oka H, Mizushima Y．Streptococcal related antigens stimulate production of IL6 and interferon γ by T cells from patients with Behcet's disease. Cell Immunol 140,410-419,1992．

52．Suzuki Y, Hoshi K, Matsuda T, Mizushima Y．Increased peripheral blood γδ+ T cells and natural killer cells in Behcet's disease. J Rheumatol 19,588-592,1992．

53．Tanihara M, Suzuki Y, Fujiwara C, Abe C, Abe E, Suda T, Mizushima Y．A synthetic peptide corresponding to 86-93 of the human type I IL-1 receptor binds human recombinant IL-1 (αand β) and inhibits IL-1 actions in vitro and in vivo. Biochem Biophys Res Com 188,912-920,1992．

54．Yamamoto K, Sakoda H, Nakajima T, Kato T, Okubo M, Dohi M, Mizushima Y, Ito K, Nishioka K．Accumulation of multiple T cell clonotypes in the synovial lesions of patients with rheumatoid arthritis revealed by a novel clonality analysis. Int Immunol 4,1219-1223,1992.